Joerg Huwyler
Joerg Huwyler
Patvirtintas el. paštas - Pagrindinis puslapis
Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications
A Wicki, D Witzigmann, V Balasubramanian, J Huwyler
Journal of controlled release 200, 138-157, 2015
Brain drug delivery of small molecules using immunoliposomes
J Huwyler, D Wu, WM Pardridge
Proceedings of the National Academy of Sciences 93 (24), 14164-14169, 1996
Pharmacological characterization of designer cathinones in vitro
LD Simmler, TA Buser, M Donzelli, Y Schramm, LH Dieu, J Huwyler, ...
British journal of pharmacology 168 (2), 458-470, 2013
The human brain endothelial cell line hCMEC/D3 as a human blood‐brain barrier model for drug transport studies
B Poller, H Gutmann, S Krähenbühl, B Weksler, I Romero, PO Couraud, ...
Journal of neurochemistry 107 (5), 1358-1368, 2008
PEG-PCL-based nanomedicines: A biodegradable drug delivery system and its application
P Grossen, D Witzigmann, S Sieber, J Huwyler
Journal of Controlled Release 260, 46-60, 2017
Relevance of p‐glycoprotein for the enteral absorption of cyclosporin A: in vitro‐in vivo correlation
G Fricker, J Drewe, J Huwyler, H Gutmann, C Beglinger
British journal of pharmacology 118 (7), 1841-1847, 1996
Drug transport to brain with targeted liposomes
A Schnyder, J Huwyler
NeuroRx 2, 99-107, 2005
Engineered nanomaterial uptake and tissue distribution: from cell to organism
H Kettiger, A Schipanski, P Wick, J Huwyler
International journal of nanomedicine, 3255-3269, 2013
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery
D Schwab, H Fischer, A Tabatabaei, S Poli, J Huwyler
Journal of medicinal chemistry 46 (9), 1716-1725, 2003
Tumor targeting using liposomal antineoplastic drugs
J Huwyler, J Drewe, S Krähenbuhl
International Journal of Nanomedicine 3 (1), 21-29, 2008
HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833
J Drewe, H Gutmann, G Fricker, M Török, C Beglinger, J Huwyler
Biochemical pharmacology 57 (10), 1147-1152, 1999
Regulation of BCRP (ABCG2) and P-glycoprotein (ABCB1) by cytokines in a model of the human blood–brain barrier
B Poller, J Drewe, S Krähenbühl, J Huwyler, H Gutmann
Cellular and molecular neurobiology 30, 63-70, 2010
Lipid-based DNA therapeutics: hallmarks of non-viral gene delivery
J Buck, P Grossen, PR Cullis, J Huwyler, D Witzigmann
ACS nano 13 (4), 3754-3782, 2019
Evidence that nicotinic α7 receptors are not involved in the hyperlocomotor and rewarding effects of nicotine
AJ Grottick, G Trube, WA Corrigall, J Huwyler, P Malherbe, R Wyler, ...
Journal of Pharmacology and Experimental Therapeutics 294 (3), 1112-1119, 2000
Directing nanoparticle biodistribution through evasion and exploitation of Stab2-dependent nanoparticle uptake
F Campbell, FL Bos, S Sieber, G Arias-Alpizar, BE Koch, J Huwyler, ...
ACS nano 12 (3), 2138-2150, 2018
The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA (“ecstasy”) in humans
CM Hysek, LD Simmler, M Ineichen, E Grouzmann, MC Hoener, ...
Clinical pharmacology & therapeutics 90 (2), 246-255, 2011
Duloxetine Inhibits Effects of MDMA (“Ecstasy") In Vitro and in Humans in a Randomized Placebo-Controlled Laboratory Study
CM Hysek, LD Simmler, VG Nicola, N Vischer, M Donzelli, S Krähenbühl, ...
PloS one 7 (5), e36476, 2012
Targeting of the photocytotoxic compound AlPcS4 to Hela cells by transferrin conjugated PEG‐liposomes
A Gijsens, A Derycke, L Missiaen, D De Vos, J Huwyler, A Eberle, ...
International journal of cancer 101 (1), 78-85, 2002
Mechanisms of increased bioavailability through amorphous solid dispersions: a review
A Schittny, J Huwyler, M Puchkov
Drug Delivery 27 (1), 110-127, 2020
Receptor mediated delivery of daunomycin using immunoliposomes: pharmacokinetics and tissue distribution in the rat
J Huwyler, J Yang, WM Pardridge
Journal of Pharmacology and Experimental Therapeutics 282 (3), 1541-1546, 1997
Sistema negali atlikti operacijos. Bandykite vėliau dar kartą.
Straipsniai 1–20